Shares of AbbVie Inc. ABBV slid 1.47% to $171.35 Wednesday, on what proved to be an all-around positive trading session for ...
AbbVie will commit less capital towards experimental medicines for psychiatric disease, CEO Robert Michael said at an ...
The schizophrenia drug Emraclidine failed to perform in clinical trials but executives say it can still “play a role.” ...
Zacks.com on MSN8h
Top Research Reports for Visa, AbbVie & Analog DevicesToday's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and ...
Shares of AbbVie Inc. (NYSE:ABBV – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the ...
We recently published a list of 10 Best Dividend Kings Stocks to Invest in Now. In this article, we are going to take a look ...
AbbVie (ABBV) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock. Over ...
AbCellera announced that it has expanded its existing collaboration with AbbVie Inc. to include the discovery of T-cell ...
AbbVie Inc. closed $31.77 below its 52-week high ($207.32), which the company reached on October 31st.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback